Lexicon Pharmaceuticals, Inc. - Wutah pendapatan triwulanan LXRX

lexpharma.com (LXRX) - logo korporat

Lexicon Pharmaceuticals production capacities are fully optimized for the manufacture of metabolic agents. Revenues are based on the sale of patented drugs through insurance funds and government programs. Quarterly sales growth with a metric value of -20.80 confirms the commercialization potential of Inpefa, making the expansion of insurance coverage and the FDA verdict key catalysts for the asset's value growth.

LXRX Tingkat wutah dodolan sajrone kuartal Lexicon Pharma (04.07.2022 - 20.11.2026)

Lexicon Pharmaceuticals, Inc. - rincian analitis lan metrik utama (LXRX)

- kuotasi saiki lan rata-rata prakiraan nilai:
- indikator dhuwit lan arus kas:
Analisis dhasar perusahaan:Lexicon Pharmaceuticals, Inc. - LXRX
Produk seri lexpharma.com

Lexicon Pharmaceuticals (LXRX) revenues depend on insurance reimbursements for high-cost drugs treating cardiac and endocrine pathologies. By analyzing the QoQ revenue growth rate, an investor assesses the real dynamics of the company's market expansion. This metric measures the speed of cash inflows between quarters, allowing one to filter out market noise and identify the true phase of the operating cycle. Such indicators are critical for evaluating the fundamental value of biotechnological assets.

Pesaing langsung

ASND - Wutah pendapatan kuartal marang kuartal|MDGL: Wutah pendapatan kuartal marang kuartal|CORT: Wutah pendapatan triwulanan|RYTM - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan kuartal marang kuartal Akero Corp|Metsera Therapeutics (MTSR) - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan kuartal marang kuartal moonlaketx.com (MLTX)|Wutah dodolan triwulanan Crinetics Pharmaceuticals CRNX|Wutah pendapatan kuartal marang kuartal NewAmsterdam Pharma N.V. NAMS|Tingkat wutah dodolan sajrone kuartal Soleno Therapeutics Inc (SLNO)|FOLD - Wutah pendapatan kuartal marang kuartal|ETNB: Wutah pendapatan kuartal marang kuartal|AGIO: Wutah pendapatan triwulanan|Structure Therapeutics Inc. - Tambahing pendapatan triwulanan|MDXG (MiMedx Corp) - Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Rezolute Inc RZLT|Wutah pendapatan triwulanan MBX|Wutah dodolan triwulanan Altimmune, Inc. ALT|Wutah pendapatan triwulanan AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Tingkat wutah pendapatan sajrone kuartal|BIOA: Wutah dodolan triwulanan|Tambahing pendapatan triwulanan BMEA (Biomea Fusion)|QNCX (quincetx.com) - Wutah dodolan triwulanan|Fractyl - Tambahing pendapatan triwulanan|VTVT (vTv Therapeutics Inc) - Wutah pendapatan triwulanan|Agape ATP - Dinamika pendapatan kuartal marang kuartal|Wutah dodolan triwulanan PLUR (Pluri Inc)|Tingkat wutah dodolan sajrone kuartal Synlogic Inc.|Wutah pendapatan kuartal marang kuartal Lipocine Inc. LPCN|Matinas BioPharma (MTNB) - Tingkat wutah pendapatan sajrone kuartal|Spruce Biosciences Inc. - Wutah pendapatan triwulanan|Tingkat wutah dodolan sajrone kuartal Galecto, Inc. GLTO|Carmell Therapeutics (CTCX) - Wutah pendapatan kuartal marang kuartal|Lumos Pharma - Tambahing pendapatan triwulanan|ONVO (Organovo Corp) - Wutah pendapatan triwulanan|Radius Pharmaceuticals (RDUS) - Tingkat wutah dodolan sajrone kuartal